AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03187587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy treatment
Description: The standard chemotherapy treamtment arm recieves only chemotherapy.
Study NCT04491916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irone sucrose
Description: drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
Study NCT04621656 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: January Mobile Application (Sugar AI)
Description: Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
Study NCT01347320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative MRI
Description: Preoperative staging
Study NCT02930135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping
Description: Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
Study NCT02930135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
Study NCT00909571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506E (modified release tacrolimus)
Description: oral
Study NCT00909571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf (tacrolimus)
Description: injection
Study NCT00529217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
Study NCT00838981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
Study NCT00838981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: placebo, sugar pill will mirror active drug
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
Study NCT00838981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
Study NCT00838981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone
Description: Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral treatment
Description: All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive behavioral treatment
Description: All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher Control
Description: Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
Study NCT00838981 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Voucher Control
Description: Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
Study NCT03102879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedure
Description: Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
Study NCT03102879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Root Canal Treatment
Description: Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
Study NCT02258425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FEM-CARE
Study NCT02908217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
Study NCT02908217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 Intravenous infusions of placebo every 4 weeks.
Study NCT02600650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testosterone boosting supplement
Description: Proprietary formulation of Testosterone boosting supplement administered daily
Study NCT02600650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Daily administration of Placebo Comparator
Study NCT02943473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.
Study NCT02162173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
Study NCT01117246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
Study NCT03256487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine 0.3mg IV
Study NCT03256487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: morphine 0.1 mg/kg IV (max 8mg per dose)
Study NCT02699411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: dry needling Travell and Simons
Study NCT02699411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stability and propioception
Description: Start excursion balance test, WOMAC; ROM, EVA.
Study NCT03471845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
Study NCT02258425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Study NCT02863744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap with subepithelial connective tissue graft
Description: * Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures.
Study NCT03181893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859 low
Description: A humanized immunoglobulin neutralizing antibody
Study NCT03181893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
Study NCT03181893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859 high
Description: A humanized immunoglobulin neutralizing antibody
Study NCT00076206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779
Study NCT00076206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03230565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patient will be given a continuous infusion of local anesthetic.
Study NCT03230565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patient will be given a scheduled intermittent bolus of local anesthetic.
Study NCT02412982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg q12h
Description: Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
Study NCT02412982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg q8h
Description: Patients receive enoxaparin 30 mg every 8 hours.
Study NCT00715806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open MRI scanner.
Description: Imaging in an Open MRI scanner.
Study NCT00715806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed MRI scanner.
Description: Imaging in a short-bore closed MRI scanner.
Study NCT02938650 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nitrosomonas eutropha
Description: Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
Study NCT03078868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Scanner
Description: MRI
Study NCT02957019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2 - Ph I
Description: Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
Study NCT02957019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2 at RD - Ph II
Description: Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
Study NCT02957019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
Study NCT00065208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Energy therapy - 8 biweekly sessions of 30 minutes
Study NCT00065208 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pretend Reiki
Description: Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
Study NCT00065208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rest / Guided Imagery
Description: 4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
Study NCT00855335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
Study NCT00855335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet twice daily up to 12 weeks postpartum.
Study NCT00855335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
Study NCT00855335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: One 25 mg tablet once daily up to 12 weeks postpartum.
Study NCT00855335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat (FDC)
Description: Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
Study NCT03163667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets
Study NCT03163667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CB-839
Description: oral tablets
Study NCT03163667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: oral tablets
Study NCT03163667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: everolimus
Description: oral tablets
Study NCT03085290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous serum eye drops
Description: Autologous serum eye drop doses will be 6 times daily in each eye
Study NCT03085290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic serum eye drops
Description: Allogeneic serum eye drop doses will be 6 times daily in each eye
Study NCT01257750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (5mg/ml)
Description: Topical pazopanib, 4 times per day for 3 weeks
Study NCT02602145 — intervention group
Intervention type: OTHER
Intervention: follow-up CTA
Description: All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
Study NCT02524405 — intervention group
Intervention type: OTHER
Intervention: Pittsburgh Compound B [11C]-PIB
Description: This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
Study NCT04406220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small clog size
Description: Participants will be randomized to run in small clogs
Study NCT04406220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large clog size
Description: Participants will be randomized to run in large clogs
Study NCT02297191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar Interfascial Plane Block
Description: All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped.
Study NCT02297191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Study NCT03838146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Types of Exercise
Description: moderate intensity exercise
Study NCT01758120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone plus cyclophosphamide
Description: 1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Study NCT02091245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Study NCT01758120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone alone
Description: 1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control
Study NCT00938574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atu027
Study NCT03528629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Description: Zolbetuximab will be administered as a 2-hour intravenous infusion.
Study NCT02820857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfiri-bevacizumab
Description: Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
Study NCT02820857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfiri
Description: Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Study NCT03417843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUSRA RF electrode
Description: At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces
Study NCT04441242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient lighting
Description: Use of ambient lighting (75-150 lux) in endoscopy room.
Study NCT04441242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low lighting
Description: Use of low lighting (\<75 lux) in endoscopy room.
Study NCT02621944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
Study NCT02621944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All participants will receive an MRI between 7-12 days of age.
Study NCT02621944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
Study NCT04345523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and derivatives.
Description: Administration of fresh plasma from donor immunized against COVID-19
Study NCT00834678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 100 or 120 mg/m2 IV on days 1 and 2
Study NCT00834678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100 or 150 mg po on days 5 - 21 of each 28 day cycle